Latest News

Conference Updates

BCMA-directed CAR T-cell Therapy Demonstrates Profound Efficacy in High-risk Smoldering Multiple Myeloma: Results from the CAR-PRISM Phase 2 Trial

High-risk smoldering multiple myeloma (HR-SMM) is a precursor to symptomatic multiple myeloma, characterized by a significantly increased risk of progression to active disease with...

AACR 2026: Next-Generation Cell Therapy Show Promise in Solid and Hematologic Malignancies

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of hematologic malignancies but have faced significant challenges in solid tumors and long-term persistence...

HOUSE DESIGN

Science & Medicine

Stay Connected

16,985FansLike
2,458FollowersFollow
61,453SubscribersSubscribe
- Advertisement -spot_img

Updates

Reviews

Review

BCMA-directed CAR T-cell Therapy Demonstrates Profound Efficacy in High-risk Smoldering Multiple Myeloma: Results from the CAR-PRISM Phase 2 Trial

High-risk smoldering multiple myeloma (HR-SMM) is a precursor to symptomatic multiple myeloma, characterized by a significantly increased risk of progression to active disease with...

AACR 2026: Next-Generation Cell Therapy Show Promise in Solid and Hematologic Malignancies

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of hematologic malignancies but have faced significant challenges in solid tumors and long-term persistence...

Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy

In early November, a team of physicians at Jiahui International Cancer Center (JICC), part of Jiahui International Hospital, Shanghai’s first large-scale international tertiary hospital,...

Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain Receive the 2025 Merkin Prize

The 2025 Richard N. Merkin Prize in Biomedical Technology was jointly awarded to Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain in a ceremony...

STAR-101 Study results Highlighted at the 17th International Mesothelioma Interest Group (iMig) 2025

Results from the first-in-humans (FIH) STAR-101 clinical study (NCT05568680), an ongoing, open-label multicenter Phase 1 clinical trial designed to evaluate the safety, feasibility, and...

Expert Interviews

High-risk smoldering multiple myeloma (HR-SMM) is a precursor to symptomatic multiple myeloma, characterized by a significantly increased risk of progression to active disease with...

Short

Company

Summary | Highlights

LATEST ARTICLES

Most Popular